Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
What is leukemia?
Leukemia is blood cancer. It develops in the bone marrow—the soft, spongy center of the long bones that produces the three major blood cells.
What is chronic myelogenous leukemia (CML)?
In chronic myelogenous leukemia (CML), the white blood cells that are affected are a specific kind called myeloid cells, or “myeloblasts.”
As you read further, you will find general information about CML. If you would like to view summary information about cancer first, see the cancer overview.
How Dana-Farber/Children’s Hospital Cancer Center approaches CML
Patients with CML are treated through Dana-Farber/Boston Children's Cancer and Blood Disorders Center, an integrated pediatric hematology and oncology partnership between Dana-Farber Cancer Institute and Boston Children’s Hospital. We understand that you may have a lot of questions when your child is diagnosed with CML. Is it dangerous? Will it affect my child long-term? What do we do next? We’ve tried to provide some answers to those questions in the following pages, and our experts can explain your child’s condition fully.
Our multidisciplinary Leukemia Program ensures in-depth discussion of each case and personalized treatment plans for every patient. Your child will receive integrated care from a team that includes the following specialists:
Expert diagnosis by pathologists using advanced molecular diagnostic testing to identify your child’s type of tumor. Knowing the molecular composition of a tumor helps predict which treatments are more likely to work.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”